Low expression of DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 6, 2012, Pages 1117-1125

  Zhang, Xiaojing ^a   Li, Ning ^a   Li, Xianzheng ^a   Zhao, Wei ^a   Qiao, Yudan ^a   Liang, Li ^a   Ding, Yanqing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

DAB2IP; Downregulation; Hepatocellular carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DAB2IP GENE; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84861469842     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07049.x     Document Type: Article

References (21)

1. Unitt E, Marshall A, Gelson W etal. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J. Hepatol. 2006; 45: 246-53.
2. Macheiner D, Heller G, Kappel S etal. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J. Hepatol. 2006; 45: 81-9.
3. Chen H, Pong RC, Wang Z, Hsieh JT. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 2002; 79: 573-81.
4. Wang Z, Tseng CP, Pong RC etal. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J. Biol. Chem. 2002; 277: 12622-31.
5. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 2005; 280: 22437-44.
6. Yano M, Toyooka S, Tsukuda K etal. Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int. J. Cancer 2005; 113: 59-66.
7. Qiu GH, Xie H, Wheelhouse N etal. Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and promoter methylation of hDAB2IPA in hepatocellular carcinoma. J. Hepatol. 2007; 46: 655-63.
8. Xie D, Gore C, Zhou J etal. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 19878-83.
9. Xie D, Gore C, Liu J etal. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc. Natl. Acad. Sci. U.S.A. 2010; 107: 2485-90.
10. Min J, Zaslavsky A, Fedele G etal. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010; 16: 286-94.
11. Dote H, Toyooka S, Tsukuda K etal. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin. Cancer Res. 2004; 10: 2082-9.
12. Chen H, Toyooka S, Gazdar AF, Hsieh JT. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J. Biol. Chem. 2003; 278: 3121-30.
13. Dote H, Toyooka S, Tsukuda K etal. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br. J. Cancer 2005; 92: 1117-25.
14. Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int. J. Mol. Med. 2006; 17: 3-13.
15. Zhou J, Wang S, Lu J, Li J, Ding Y. Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Int. J. Cancer 2009; 124: 1879-86.
16. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 2004; 10: 8465-71.
17. Kwon JH, Kim J, Park JY etal. Overexpression of high-mobility group box 2 is associated with tumor aggressiveness and prognosis of hepatocellular carcinoma. Clin. Cancer Res. 2010; 16: 5511-21.
18. Ding Y, Chen B, Wang S etal. Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int. J. Cancer 2009; 124: 653-8.
19. Lü WP, Dong JH, Huang ZQ, Shi S, Guo DY, Liu YS. Clinical related factors of portal vein tumor thrombosis in patients with hepatocellular carcinoma: a logistic regression analysis. Zhonghua Wai Ke Za Zhi 2008; 46: 733-6.
20. Calvisi DF, Ladu S, Conner EA etal. Pase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol. 2011; 54: 311-19.
21. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the arossroads of development and tumor metastasis. Dev. Cell 2008; 14: 818-29.